Canaccord Genuity Maintains Buy on Clover Health Investments, Lowers Price Target to $3.2
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and lowers the price target from $3.7 to $3.2.
Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and lowers the price target from $3.7 to $3.2.